ResMed Inc (NYSE: RMD) director exercises options and sells 2,575 shares

Rhea-AI Filing Summary

ResMed Inc director John Hernandez exercised options for 2,575 shares of ResMed Common Stock at $148.9000 per share on August 18, 2025, then sold 2,575 shares at a weighted average price of $287.1026. Following these transactions, he holds 4,045 common shares directly.

Insights

Financial Analyst

TL;DR: Routine option exercise and sale by a director, modest net reduction in ownership.

John Hernandez exercised 2,575 options at a strike of $148.90 and simultaneously sold 2,575 shares at a weighted average of $287.1026, realizing a material per-share gain versus strike price. The director's reported beneficial holding fell to 4,045 shares from 6,620, a decline of ~39%. This is a standard compensation-related liquidity action rather than an operational signal from the company. Impact on share count and potential dilution is immaterial at the company level given the small absolute share count relative to a large-cap issuer.

Corporate Governance Expert

TL;DR: Transaction appears consistent with option vesting and routine director liquidity; disclosure is timely and complete.

The Form 4 shows an exercise (code M) and an immediate sale (code S) executed the same day, with full disclosure of price range and weighted average sale price. Vesting terms cited (exercisable 11/11/2024 or at next annual meeting) explain timing. From a governance perspective, the filing meets Section 16 transparency requirements; the reduction in beneficial ownership is notable but not large enough alone to indicate governance issues.

Insider Trade Summary

Exercise and Sale: 2,575 shares ($356K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Hernandez John

Role Director

Sold 2,575 shs ($739K)

Approx. gross sale proceeds $739K

Approx. exercise cost $383K

Approx. pre-tax spread $356K

Type	Security	Shares	Price	Value
Exercise	ResMed Common Stock Options	2,575	$0.00	$0.00
Exercise	ResMed Common Stock	2,575	$148.90	$383K
Sale	ResMed Common Stock	2,575	$287.1026	$739K

Holdings After Transaction: ResMed Common Stock Options — 0 shares (Direct); ResMed Common Stock — 4,045 shares (Direct)

Footnotes (2)

1. F1. This transaction was executed in multiple trades at prices ranging from $286.90 - $287.24. The price reported above reflects the weighted average sale price.
2. F2. Represents the date options become exercisable. Options vest in full (i) on the first Nov. 11 following the grant date or (ii) the first annual shareholders meeting following grant date.

Key Figures

Options exercised: 2,575.0000 shares Option exercise price: $148.9000 per share Weighted average sale price: $287.1026 per share +2 more

5 metrics

Options exercised 2,575.0000 shares ResMed Common Stock Options exercised on 2025-08-18

Option exercise price $148.9000 per share Exercise price for ResMed Common Stock Options

Weighted average sale price $287.1026 per share Sale of 2,575 ResMed Common Stock shares on 2025-08-18

Sale price range $286.90–$287.24 per share Multiple trades comprising the reported weighted average sale price

Post-transaction holdings 4,045 shares Direct ResMed Common Stock held after reported transactions

Key Terms

ResMed Common Stock Options, weighted average sale price, vest in full, annual shareholders meeting

4 terms

ResMed Common Stock Options financial

"security_title: ResMed Common Stock Options"

weighted average sale price financial

"The price reported above reflects the weighted average sale price."

vest in full financial

"Options vest in full on specified future dates after grant."

annual shareholders meeting financial

"the first annual shareholders meeting following grant date"

An annual shareholders meeting is a yearly gathering where owners of a company review its performance, hear presentations from management, ask questions, and vote on important items such as board members, executive pay, and dividend policies. Think of it as a company town hall where votes and discussions can change leadership, strategy or payouts—outcomes that can directly affect a stock’s future performance and an investor’s rights and returns.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 08/19/2025 - 01:10 PM Learn about SEC filing dates

FAQ

What insider transactions did ResMed Inc (RMD) director John Hernandez report?

He exercised options for 2,575 shares at $148.9000 per share and then sold 2,575 shares at a weighted average $287.1026. These trades were reported in a Form 4 insider filing with the SEC.

How many ResMed Inc (RMD) shares does John Hernandez own after the Form 4?

After the reported transactions, John Hernandez directly holds 4,045 ResMed Common Stock shares. This post-transaction balance reflects his remaining ownership position as disclosed in the filing’s canonical holdings data.

At what prices were John Hernandez’s ResMed Inc (RMD) shares sold?

He sold 2,575 shares at a weighted average price of $287.1026 per share. The sale was executed in multiple trades, with individual prices ranging between $286.90 and $287.24, according to the filing footnote.

What were the key terms of John Hernandez’s ResMed Inc (RMD) stock options?

The options covered 2,575 shares with an exercise price of $148.9000 per share, exercisable from November 11, 2024 and expiring on November 16, 2030. A footnote explains they vest in full on specific future dates.

Did the ResMed Inc (RMD) Form 4 show a net purchase or sale of shares?

The filing reflects a net sale of 2,575 shares. Hernandez exercised options to acquire 2,575 shares and then sold the same number, resulting in netBuySellShares of -2,575 and a net-sell direction in the transaction summary.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hernandez John

(Last) (First) (Middle)

9001 SPECTRUM CENTER BLVD.

(Street)

SAN DIEGO CA 92123

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RESMED INC [ RMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
ResMed Common Stock	08/18/2025		M		2,575	A	$148.9	6,620	D
ResMed Common Stock	08/18/2025		S		2,575	D	$287.1026(1)	4,045	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
ResMed Common Stock Options	$148.9	08/18/2025		M			2,575	11/11/2024(2)	11/16/2030	ResMed Common Stock	2,575	$0	0	D

Explanation of Responses:

1. This transaction was executed in multiple trades at prices ranging from $286.90 - $287.24. The price reported above reflects the weighted average sale price.

2. Represents the date options become exercisable. Options vest in full (i) on the first Nov. 11 following the grant date or (ii) the first annual shareholders meeting following grant date.

	John Hernandez, Director	08/19/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.